



### **Agenda**

- HY 2021 Highlights
- HY 2021 Financial Review
- Outlook
- Q&A

#### Speakers




Peter Kruithof, CFO

Tako de Haan, CEO





# **Progress on strategy - HY 2021**





### **HY 2021 – Financial highlights**

Turnover	<ul> <li>Overall: - 1.5% to € 823.6 M (+ 2.3% on a constant currency basis)</li> <li>Organic: - 2.9% (+ 0.9% on a constant currency basis)</li> </ul>		
EBITDA	• EBITDA of <b>€ 45.6 M</b> (2020: € 35.3	3 million)	
Cash flow	<ul> <li>Net cash from operations of -€ 29.1 M (2020: € 70.4 M)</li> <li>Inventory in days: 87 (2020: 78)</li> <li>Debtors in days: 33 (2020: 35)</li> <li>Return on invested working capital 22.8% (2020: 21.9%)</li> </ul>		
Business segment contribution (Turnover)	<ul> <li>B&amp;S Liquors -3.5%</li> <li>B&amp;S Beauty 12.4%</li> <li>B&amp;S Personal Care 6.9%</li> </ul>	<ul> <li>B&amp;S Food -12.8%</li> <li>B&amp;S Health -28.7%</li> <li>B&amp;S Retail -61.3%</li> </ul>	
Acquisitive growth	• <b>Top Care</b> contributed € 11.8 M to	the B&S Beauty segment in HY - Consolidated within the	

as from August 2020

- Top Care contributed € 11.8 M to the B&S Beauty segment in HY - Consolidated within the Group



## **Business segment performance HY 2021**

	•	•	•	•	•	•
	B&S Liquor	B&S Beauty	B&S Personal Care	B&S Food	B&S Health	B&S Retail
	Focus on higher margin business paid off in our international Liquor business. Further sales growth held back by industry wide product scarcity and freight delays.  European wholesale sales levels back to pre-Covid levels with increased margins.	Significant EUR / USD impact, yet sales grew by 13.8% organically at constant currency.  Further growth held back by scarcity in the market  Margins starting to get back to pre-Covid levels from Q2 onwards.	Outperformed H1 2020 but continued to face the effects from lockdown measures in the value retail market.  Indirect Covid-19 impact from increased international freight rates, affecting margins mainly in private label assortment.	Pressure on remote business following troops withdrawal from Afghanistan.  Travel related market recovery slower than expected.  International brand distribution services outperformed 2020 levels.	Turnover and margin declined;  Market for Covid-19 related products with higher margins stabilized in the second half of 2020.  Travel vaccine business below 2020 levels due to ongoing global travel restrictions.	Recovery international travel sector slower than expected.  Q2 2021 sales levels lower than previously anticipated.  Not expected to reach break-even level by end 2021.
Turnover	€230.9 M	€ 302.0 M	€ 124.7 M	€ 132.9 M	€22.5 M	€ 10.5 M
Gross profit	€23.5 M	€ 57.6 M	€19.2 M	€19.4 M	€3.8 M	€2.3 M
EBITDA	€9.4 M	€27.7 M	€ 8.4 M	€3.7 M	€1.0 M	€ (3.8) M





FINANCIAL REVIEW HY 2021



#### **Key figures HY 2021**


€ million (unless stated otherwise)	HY 2021		IY 2021 onstant		IY 2020		Δ %
Profit or loss account							
Turnover	823.6		855.3		835.8		-1.5%
Gross profit (margin)	126.8	15.4%	132.3	15.5%	114.9	13.7%	10.4%
EBITDA (margin)	45.6	5.5%	49.4	5.8%	35.2	4.2%	29.2%
Profit before tax	28.5				14.9		91.3%
Profit attributable to Owners	14.7				5.7		157.9%
EPS (in Euro)	0.17				0.07		

€ million (unless stated otherwise)	Q2 2021	Q2 2021 constant FX	Q2 2020	Δ %
Profit or loss account				
Turnover	428.1	444.7	415.3	3.1%

- Turnover decline of 1.5% compared to HY 2020; FX effect 3.8%;
- Gross profit increased while operational expenses remained at similar levels, resulting in an EBITDA growth of 29.2%;
- EBITDA at constant currency € 49.4 M (HY 2020: € 31.9 corrected for government grants)
- Net profit attributable to the owners of the Company came in at € 14.7 M (HY 2020: € 5.7 M) mainly as a result of margin growth in the B&S Liquor segment and growth of Beauty segment.




### Overall turnover development analysis HY 2021



- Covid-19 impact lasted longer than anticipated; impact in Q1 2020 was limited;
- The acquisition Top Care contributed € 11.8 M;
- The development of the EUR/USD exchange rate had a negative impact of € 31.7 M on turnover.



#### Overall turnover development analysis Q2 2021



- Despite Covid-19 impact lasting longer than expected turnover grew 5.5% organically at constant currency;
- The acquisition Top Care contributed € 6.6 M;
- The development of the EUR/USD exchange rate had a negative impact of € 16.6 M on turnover.



#### **Financial position**


€ million (unless stated otherwise)	HY 2021	HY 2020	
Financial position			
Solvency ratio	34.3%	37.2%	
Net debt *	247.3	239.6	
Net debt / EBITDA *	2.8	2.8	
Inventory in days	87	78	
Working capital in days	96	92	
ROIWC	22.8%	21.9%	

- Net debt increased as a result of inventory buildup related to our seasonally stronger H2 and particularly Q4;
- ROIWC increased as EBITDA growth outpaced working capital growth.

<sup>\*</sup> Excluding IFRS 16 lease liability.



## Net debt development HY 2021





### Working capital development

€ million (unless stated otherwise)	HY 2021	HY 2020	
Inventory	375.6	355.4	
(days)	87	78	
Trade Receivables	167.5	181.7	
(days)	33	35	
Trade Payables	101.0	93.3	
(days)	23	21	
Working capital	442.1	443.7	
(days)	96	92	


- Inventory in days and working capital in days increased as a result of inventory buildup related to our seasonally stronger H2 and particularly Q4;
- Trade receivables decreased as a result of continued strict credit control.





#### We aim to continue our exciting growth story

**Financial objectives 2021-2023** 





#### Outlook H2 2021

Short term growth below expectations

- Covid-19 impact travel related markets lasts longer than anticipated
- Product scarcity in markets expected to continue
- Indirect Covid-19 impact on supply chain expected to continue
- FX effect especially on B2C business in US impacting growth

EBITDA margin objective of >6% expected feasible

- Further execution Digital First program
- Focus on online channels, assortment and gross profit
- Continued cost control
- Continued process optimization

Net debt / EBITDA and ROIWC objectives reiterated

 Continued focus on working capital management throughout all segments



Q&A HY 2021

